NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00841828,Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients,https://clinicaltrials.gov/study/NCT00841828,,COMPLETED,Phase II randomized multicenter trial to compare Epirubicin and Cyclophosphamide plus Docetaxel and Trastuzumab with Epirubicin and Cyclophosphamide plus Docetaxel and Lapatinib for patients with positive HER2 and resectable or locally advanced breast cancer.,YES,Breast Cancer,DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Lapatinib|DRUG: Trastuzumab,"Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D)., Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response. According to the Miller\&Payne Criteria, pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D., Up to 16 weeks","Overall Clinical Response Rate (ORR), Overall clinical response was evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria (Therasse et al, 2000). Is defined as the sum of Complete responses plus Partial responses.

It was evaluated after the fourth EC cycle and before surgery using ultrasound, mammography, or MRI., Up to 12 weeks",,Spanish Breast Cancer Research Group,GlaxoSmithKline,FEMALE,"ADULT, OLDER_ADULT",PHASE2,102,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GEICAM/2006-14|2007-007031-13,2009-02,2011-12,2013-12,2009-02-11,2018-11-02,2023-03-31,"Hospital Central de Asturias, Oviedo, Asturias, 33006, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Hospital General de Granollers, Granollers, Barcelona, 08400, Spain|Xarxa Asistencial de Manresa, Manresa, Barcelona, 08243, Spain|Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, 08208, Spain|Hospital del Espíritu Santo, Santa Coloma De Gramenet, Barcelona, 08923, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, 08221, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, 08221, Spain|Onkologikoa, Donostia-San Sebastián, Guipuzcoa, 20012, Spain|Hospital Xeral Cíes, Vigo, Pontevedra, 36204, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, 38320, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, 15006, Spain|Centro Oncológico de Galicia, A Coruña, 15009, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Clinic i Provincial, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital General Yagüe, Burgos, 09005, Spain|Complejo Hospitalario San Pedro de Alcántara, Cáceres, 10003, Spain|Complejo Hospitalario Universitario Reina Sofía, Córdoba, 14004, Spain|Complejo Hospitalario de Jaén, Jaén, 23007, Spain|Hospital Universitario de la Princesa, Madrid, 28006, Spain|Hospital Clínico Universitario Virgen de la Victoria, Málaga, 29010, Spain|Hospital Virgen de la Salud, Toledo, 45004, Spain|Hospital Universitario La Fe, Valencia, 46009, Spain|Hospital Clinico Universitario de Valencia, Valencia, 46010, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain",
